Eurazeo invests in Imapôle in European market’s third healthcare deal in a week

• The Nov Santé Actions Non Cotées fund was initiated by France Assureurs and Caisse des Dépôts and is managed by Eurazeo
• The fund has acquired a minority stake alongside the founders
• Imapôle generated revenue of around €15 million in 2021

The Nov Santé Actions Non Cotées fund, managed by Eurazeo, alongside Bpifrance  has completed an investment of more than €50 million in French medical imaging company Imapôle. The Nov Santé Actions Non Cotées fund was initiated by France Assureurs and Caisse des Dépôts.

Imapôle was founded in 2018 and is based in Lyon, France. The company generated revenue of around €15 million in 2021 and has seen revenues grow at an average rate of over 8 percent per year in the last few years.

“Nov Santé fund’s dedicated team is very happy to be working with Imapôle on its next expansion phase, and to bring Eurazeo’s expertise in healthcare and private equity,” said Arnaud Vincent, managing director of the Nov Santé Actions Non Cotées fund. “For the first time since the fund was launched, we are investing in the healthcare operators’ segment through a group whose medical project is at the core of its strategy and that is using the latest technologies to address medical deserts and make diagnostics more reliable, in line with Nov Santé’s objectives.”

The Nov Santé Actions Non Cotées fund was launched in March 2021. The fund provides funding to healthcare SMEs in France with the aim of making France more self-sufficient in healthcare. It has raised €420 million and makes equity or near-equity investments of between €10 million and €40 million per company.

Eurazeo is a French global investor headquartered in Paris. The firm has $32 billion in assets under management.